ELF1: A Drug Target / Disease Biomarker (G1997)
ELF1: A Drug Target / Disease Biomarker
ELF1, also known as exonuclease-1, is a protein that is expressed in many different tissues and cells in the human body. It is a key regulator of the exonuclease activity of T cells, which are a type of white blood cell that play a crucial role in the immune system. In recent years, researchers have become interested in studying ELF1 as a potential drug target or biomarker because of its unique structure and its ability to interact with a variety of molecules.
The protein encoded by the ELF1 gene is made up of 164 amino acid residues and has a calculated molecular mass of 19.1 kDa. It is found in various tissues and cells throughout the body, including the brain, spinal cord, heart, and testes. ELF1 is primarily expressed in T cells, which are a type of white blood cell that play a crucial role in the immune system. T cells are responsible for recognizing and responding to foreign substances in the body, and they are an important part of the immune system because they help to protect the body against infection and disease.
One of the unique features of ELF1 is its ability to interact with a variety of different molecules. For example, ELF1 has been shown to interact with the protein PDGF-BB, which is a key regulator of cell growth and differentiation. This interaction between ELF1 and PDGF-BB has led some researchers to consider ELF1 as a potential drug target or biomarker for the treatment of various diseases.
Another potential mechanism by which ELF1 may be involved in the development and progression of cancer is its role in cell signaling. ELF1 has been shown to play a role in regulating the activity of various signaling pathways, including the TGF-β pathway. This pathway is involved in cell signaling and has been implicated in the development and progression of many different types of cancer. By interacting with the protein FGF1, which is a key component of the TGF-β pathway, ELF1 may be involved in the regulation of cell growth and differentiation, and this may contribute to the development and progression of cancer.
In addition to its potential role in cell signaling, ELF1 has also been shown to be involved in the regulation of inflammation. ELF1 has been shown to interact with the protein NF-kappa-B, which is a key regulator of inflammation. This interaction between ELF1 and NF-kappa-B may contribute to the regulation of inflammation and the development of various inflammatory diseases.
ELF1 has also been shown to play a role in the regulation of cellular processes that are important for maintaining cellular structure and function. For example, ELF1 has been shown to interact with the protein F-actin, which is involved in the regulation of cell adhesion. This interaction between ELF1 and F-actin may contribute to the regulation of cell adhesion and the development of various diseases.
In conclusion, ELF1 is a protein that has been shown to play a role in a variety of cellular processes that are important for maintaining cellular structure and function. Its unique structure and its ability to interact with a variety of different molecules make ELF1 an intriguing potential drug target or biomarker for the treatment of various diseases. Further research is needed to fully understand the role of ELF1 in the immune system and in the development and progression of cancer, and to determine the most effective way to use it as a therapeutic agent.
Protein Name: E74 Like ETS Transcription Factor 1
Functions: Transcription factor that activates the LYN and BLK promoters. Appears to be required for the T-cell-receptor-mediated trans activation of HIV-2 gene expression. Binds specifically to two purine-rich motifs in the HIV-2 enhancer
The "ELF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELF1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex
